靶向活检、病灶周围活检、随机活检及其组合在主动监测确诊活检中基于mpMRI/经直肠超声融合活检检测临床显著前列腺癌的作用
前瞻性收集112例低危或极低危前列腺癌患者,在主动监测方案中行mpMRI/经直肠超声融合活检,比较不同活检方案的诊断率。在靶向活检基础上增加4针病灶周围活检、14针和24针随机活检,Gleason分级分组≥2癌的检出率分别增至30%、39%和49%(所有p值<0.01)。作者结论认为病灶周围活检较单纯靶向活检提高了Gleason分级分组≥2癌的检出率,但联合方案仍漏诊较大比例的临床显著癌。
要点
- 在靶向活检基础上增加4针病灶周围活检、14针和24针随机活检,Gleason分级分组≥2癌检出率分别增至30%、39%和49%(所有p值<0.01)。
- 单纯靶向活检、14针随机活检和24针随机活检分别识别了全部Gleason分级分组≥2癌的38%、47%和56%。
- 在靶向活检基础上加4针病灶周围活检后该比例增至62%,加14针随机活检后增至80%。
核心结论
- 病灶周围活检较单纯靶向活检提高了Gleason分级分组≥2癌的检出率,但靶向活检联合病灶周围活检漏诊了较大比例经更大范围随机活检识别的临床显著癌,包括20%仅由靶向活检联合24针随机活检诊断的临床显著癌。
研究设计与样本
- 前瞻性收集112例低危或极低危前列腺癌患者的数据,这些患者mpMRI阳性,在单家学术机构主动监测方案背景下接受活检。
- 干预为使用Hitachi RVS系统的mpMRI/经直肠超声融合活检,包括3针靶向活检并同步经直肠24针随机活检。
- 采用McNemar检验比较不同活检方案(仅靶向活检;靶向活检+4针病灶周围活检;靶向活检+12针随机活检;靶向活检+24针随机活检)的诊断率。
- 采用单变量和多变量回归分析识别任何癌、Gleason分级分组≥2癌以及仅在较大方案中出现的Gleason分级分组≥2癌的预测因素。
主要发现
- 在靶向活检基础上增加4针病灶周围活检、14针和24针随机活检,Gleason分级分组≥2癌的检出率分别增至30%、39%和49%(所有p值<0.01)。
- 总体而言,单纯靶向活检、14针随机活检和24针随机活检分别识别了全部Gleason分级分组≥2癌的38%、47%和56%。
- 在靶向活检基础上加4针病灶周围活检后该比例增至62%,加14针随机活检后增至80%。
- 大多数差异见于PI-RADS 4病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Based on the findings of different trials in biopsy naïve patients, target biopsy (TB) plus random biopsy (RB) during mpMRI-guided transrectal ultrasound fusion biopsy (FB) are often also adopted for the biopsy performed during active surveillance (AS) programs. At the moment, a clear consensus on the extent and modalities of the procedure is lacking. OBJECTIVE: To evaluate the increase in diagnostic accuracy achieved by perilesional biopsy (PL) and different RB schemes during FB performed in AS protocol. DESIGN, SETTING, AND PARTICIPANTS: We collected prospectively the data of 112 consecutive patients with low- or very-low-risk prostate cancer; positive mpMRI underwent biopsy at a single academic institution in the context of an AS protocol. INTERVENTION(S): mpMRI/transrectal US FB with Hitachi RVS system with 3 TB and concurrent transrectal 24-core RB. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnostic yield of the different possible biopsy schemes (TB only; TB + 4 perilesional (PL) cores; TB + 12-core RB; TB + 24-core RB) was compared by the McNemar test. Univariable and multivariable regression analyses were adopted to identify predictors of any cancer, Gleason grade group (GGG) ≥2 cancers, and the presence of GGG≥2 cancers in the larger schemes only. RESULTS AND LIMITATIONS: The detection rate of GGG ≥2 cancers increased to 30%, 39%, and 49% by adding 4 PL cores, 14, and 24 RB cores, respectively, to TB cores (all p values <0.01). On the whole, TB alone, 14-core RB, and 24-core-RB identified 38%, 47%, and 56% of all the GGG ≥2 cancers. Such figures increased to 62% by adding to TB 4 PL cores, and to 80% by adding 14 RB cores. Most of the differences were observed in PI-RADS 4 lesions. CONCLUSIONS: We found that PL biopsy increased the detection rate of GGG ≥2 cancers as compared with TB alone. However, the combination of those cores missed a large percentage of the CS cancers identified with larger RB cores, including a 20% of CS cancers diagnosed only by the combination of TB plus 24-core RB.
引用
- Novara G, Zattoni F, Zecchini G, et al. Role of targeted biopsy, perilesional biopsy, random biopsy, and their combination in the detection of clinically significant prostate cancer by mpMRI/transrectal ultrasonography fusion biopsy in confirmatory biopsy during active surveillance program. Prostate Cancer Prostatic Dis. 2023. PMID: 37828151. doi:10.1038/s41391-023-00733-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。